The effects of losartan versus beta-blockers on cardiovascular protection in marfan syndrome: A systematic review and meta-analysis.
CONCLUSION: For cardiovascular protection in MFS, only-ARB therapy is not inferior to only-BB therapy. Moreover, the outcomes of ARB-plus-BB therapy seemed to be favourable to those of only-BB therapy.
PMID: 31003918 [PubMed - as supplied by publisher]
Source: J Formos Med Assoc - Category: General Medicine Authors: Kang YN, Chi SC, Wu MH, Chiu HH Tags: J Formos Med Assoc Source Type: research
More News: Beta-Blockers | Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Cozaar | Databases & Libraries | General Medicine | Heart | Losartan | Marfan Syndrome | Science | Study